Constandina E O'Connell - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Cancer Research|March 9, 2021

Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer CellsConstandina E O'Connell, Alex Vassilev

Stem Cell Reports|January 22, 2022

Selective elimination of pluripotent stem cells by PIKfyve specific inhibitorsArup R Chakraborty, Alex Vassilev, Sushil K Jaiswal, et al.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 16, 2025

Genomic Characteristics Related to Histology-Based Immune Features in Breast CancerYoon Jin Cha, Constandina E O'Connell, Benjamin C Calhoun, et al.

Nature Communications|February 16, 2026

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Cancer Research|March 9, 2021

Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer CellsConstandina E O'Connell, Alex Vassilev

Stem Cell Reports|January 22, 2022

Selective elimination of pluripotent stem cells by PIKfyve specific inhibitorsArup R Chakraborty, Alex Vassilev, Sushil K Jaiswal, et al.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 16, 2025

Genomic Characteristics Related to Histology-Based Immune Features in Breast CancerYoon Jin Cha, Constandina E O'Connell, Benjamin C Calhoun, et al.

Nature Communications|February 16, 2026

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.

Pageof 1